Abstract 94P
Background
Molecular profiling has revolutionized cancer treatment by identifying tumor-specific alterations, enabling the use of molecular-guided therapies. This study assessed the impact of an online continuing medical education (CME) activity on clinicians' knowledge and confidence in implementing molecular testing in oncology care.
Methods
This CME activity consisted of a 30-minute video discussion between 2 expert faculty with synchronised slides. Educational effect was assessed using a repeated-pair design with pre-/post-assessment. 3 multiple-choice questions assessed knowledge, and 1 Likert-scale question assessed confidence, with each individual serving as their own control. A McNemar’s test assessed significance of improvement in the percentage of correct responses to knowledge questions from pre- to post-assessment. P values < .05 are statistically significant. The activity launched on May 30, 2024, with data collected through July 18, 2024 being reported in the current study.
Results
59 oncologists and 31 pathologists who answered all questions were included in this study. A significant improvement in overall knowledge of both learner groups was observed, with 7 times more oncologists and 5 times more pathologists answering all questions correctly after education. Specifically, knowledge of molecular testing recommendations increased from 28% pre- to 48% post-CME for oncologists (P<.001) and from 24% pre- to 40% post-CME (P<.05) for pathologists, respectively. Knowledge of the role of molecular tumor boards increased from 22% pre- to 51% post-CME for oncologists (P<.001) and from 26% pre- to 65% post-CME (P<.01) for pathologists, respectively. Additionally, 22% of oncologists and 52% of pathologists reported increased confidence in identifying patients for molecular-guided treatment, with average increases of 47% and 77%, respectively.
Conclusions
This analysis demonstrates the positive impact of online CME on molecular testing knowledge among physicians. Continued education on patient identification for molecular-guided treatment is key for translating precision oncology advances into improved patient outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.